Business Description
ALX Oncology Holdings Inc
NAICS : 541714
SIC : 2834
ISIN : US00166B1052
Share Class Description:
ALXO: Ordinary SharesDescription
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 10.63 | |||||
| Equity-to-Asset | 0.78 | |||||
| Debt-to-Equity | 0.09 | |||||
| Debt-to-EBITDA | -0.11 | |||||
| Piotroski F-Score | 1/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -16.2 | |||||
| 3-Year EPS without NRI Growth Rate | -11 | |||||
| 3-Year FCF Growth Rate | -13.9 | |||||
| 3-Year Book Growth Rate | -29.4 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 75.2 | |||||
| 9-Day RSI | 71.72 | |||||
| 14-Day RSI | 67.42 | |||||
| 6-1 Month Momentum % | 72.86 | |||||
| 12-1 Month Momentum % | 113.48 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 5.24 | |||||
| Quick Ratio | 5.24 | |||||
| Cash Ratio | 5.08 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -7.8 | |||||
| Shareholder Yield % | -0.84 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -74.79 | |||||
| ROA % | -62.17 | |||||
| ROIC % | -404.61 | |||||
| ROC (Joel Greenblatt) % | -1622.28 | |||||
| ROCE % | -68.98 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 4.44 | |||||
| Price-to-Tangible-Book | 4.44 | |||||
| EV-to-EBIT | -4.1 | |||||
| EV-to-Forward-EBIT | -3.9 | |||||
| EV-to-EBITDA | -4.13 | |||||
| EV-to-Forward-EBITDA | -3.92 | |||||
| EV-to-Forward-Revenue | 119.19 | |||||
| EV-to-FCF | -4.96 | |||||
| Price-to-Net-Current-Asset-Value | 6.2 | |||||
| Price-to-Net-Cash | 6.49 | |||||
| Earnings Yield (Greenblatt) % | -24.39 | |||||
| FCF Yield % | -15.45 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ALXO
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
ALX Oncology Holdings Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -3.74 | ||
| Beta | 0.7 | ||
| Volatility % | 115.65 | ||
| 14-Day RSI | 67.42 | ||
| 14-Day ATR ($) | 1.160487 | ||
| 20-Day SMA ($) | 13.386 | ||
| 12-1 Month Momentum % | 113.48 | ||
| 52-Week Range ($) | 3.9357 - 17.42 | ||
| Shares Outstanding (Mil) | 50.5 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
ALX Oncology Holdings Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
ALX Oncology Holdings Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
ALX Oncology Holdings Inc Frequently Asked Questions
What is ALX Oncology Holdings Inc(ALXO)'s stock price today?
The current price of ALXO is $16.87. The 52 week high of ALXO is $17.42 and 52 week low is $3.94.
When is next earnings date of ALX Oncology Holdings Inc(ALXO)?
The next earnings date of ALX Oncology Holdings Inc(ALXO) is 2024-05-10 Est..
Does ALX Oncology Holdings Inc(ALXO) pay dividends? If so, how much?
ALX Oncology Holdings Inc(ALXO) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers